These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 29256535)

  • 41. The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
    Krasuski RA; Devendra GP; Cater G; Whitney EJ
    Am J Med Sci; 2011 May; 341(5):378-82. PubMed ID: 21358314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats.
    Rizvi F; Iftikhar M; George JP
    J Med Food; 2003; 6(2):123-8. PubMed ID: 12935323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease.
    Yaghoubi M; Jafari S; Sajedi B; Gohari S; Akbarieh S; Heydari AH; Jameshoorani M
    Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1385-1388. PubMed ID: 29023319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC; Bullano MF; Willey VJ; Cziraky MJ; Corbelli ME; Waugh W
    Am J Cardiol; 2002 Dec; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract]   [Full Text] [Related]  

  • 45. Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
    Wessels B; Ciapaite J; van den Broek NM; Houten SM; Nicolay K; Prompers JJ
    Diabetes Obes Metab; 2015 Jan; 17(1):52-60. PubMed ID: 25200673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
    Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.
    Tanaka A; Komukai S; Shibata Y; Yokoi H; Iwasaki Y; Kawasaki T; Horiuchi K; Nakao K; Ueno T; Nakashima H; Tamashiro M; Hikichi Y; Shimomura M; Tago M; Toyoda S; Inoue T; Kawaguchi A; Node K;
    Heart Vessels; 2018 Sep; 33(9):965-977. PubMed ID: 29487991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Troglitazone interferes with gemfibrozil's lipid-lowering action.
    Bell DS; Ovalle F
    Diabetes Care; 1998 Nov; 21(11):2028-9. PubMed ID: 9802763
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
    Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
    Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Preventive effects of pioglitazone on diabetes and relevant mechanisms, experimental study on non-obese diabetic mice].
    Pei JH; Zhou ZG; Luo JH; Jiang TJ; Li X; He L
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):411-5. PubMed ID: 15061998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
    Vázquez M; Zambón D; Hernández Y; Adzet T; Merlos M; Ros E; Laguna JC
    Br J Clin Pharmacol; 1998 Mar; 45(3):265-9. PubMed ID: 9517370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination lipid therapy in type 2 diabetes mellitus.
    Vergès B
    Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis.
    Basaranoglu M; Acbay O; Sonsuz A
    J Hepatol; 1999 Aug; 31(2):384. PubMed ID: 10453959
    [No Abstract]   [Full Text] [Related]  

  • 60. Pioglitazone for prevention of cognitive impairment: results and lessons.
    Sánchez-Valle R
    Lancet Neurol; 2021 Jul; 20(7):500-502. PubMed ID: 34146499
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.